Key result
Inhibition of circ-ZNF609 attenuates cardiac hypertrophy and remodeling in mice by suppressing ZEB1.
Why the study?
Effective therapeutic strategies to reverse heart failure are lacking, motivating investigation into the mechanisms underlying cardiac remodeling to identify potential therapeutic targets.
Does circ-ZNF609 inhibition attenuate pathological cardiac remodeling and hypertrophy in mice with transverse aortic constriction?
Does circ-ZNF609 inhibition attenuate pathological cardiac remodeling and hypertrophy in mice with transverse aortic constriction?
Preclinical evidence demonstrates that targeting circ-ZNF609 via shRNA or hfCas13x-crRNA attenuates pathological cardiac remodeling and hypertrophy in mice by suppressing ZEB1 expression.
Answers are grounded in this paper and cite their sources.
Preclinical mouse data preclude clinical adoption; leaves open whether circRNA targeting will translate to human heart failure.
Currently, there are no effective therapeutic strategies to reverse heart failure. This study aims to investigate mechanisms underlying cardiac remodeling and identify potential therapeutic targets. Here, we demonstrate that circ-ZNF609 is upregulated in cardiac tissue, isolated adult cardiomyocytes, and cardiac fibroblasts 4 weeks after transverse aortic constriction (TAC) in mice. Small hairpin RNA (shRNA)-mediated silencing of circ-ZNF609 attenuates TAC-induced cardiac remodeling. To further assess its therapeutic potential, we use an RNA-targeting hf Cas13x-crRNA system and show that circ-ZNF609 inhibition attenuates established cardiac hypertrophy in mice. In vitro , circ-ZNF609 inhibition reduces cardiomyocyte hypertrophy and fibroblast differentiation into myofibroblasts. Mechanistically, circ-ZNF609 interacts with YTHDF3 in an m 6 A-dependent manner to regulate ZEB1 (zinc finger E-box-binding homeobox 1) expression. circ-ZNF609 inhibition suppresses ZEB1. YTHDF3 knockdown also protects against cardiac remodeling. These findings support circ-ZNF609 inhibition as a potential therapeutic approach for pathological cardiac remodeling and heart failure.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Cardiac remodeling and hypertrophy (transverse aortic constriction mouse model). circ-ZNF609 inhibition via shRNA-mediated silencing or RNA-targeting hfCas13x-crRNA system was evaluated on TAC-induced cardiac remodeling and established cardiac hypertrophy. Inhibition of circ-ZNF609 via shRNA or an hfCas13x-crRNA system attenuated TAC-induced cardiac remodeling and established cardiac hypertrophy in mice by suppressing ZEB1.
Synapse has enriched 10 related papers. Consider them for comparative context: